Solid Biosciences announces new preclinical data for Duchenne med

Solid Biosciences announced the presentation of new preclinical data from its gene therapy development programs for Duchenne muscular dystrophy. New data for SGT-001, the company’s lead microdystrophin gene transfer candidate, further demonstrate its potential to produce long-term and body-wide microdystrophin expression that correlates with significant improvements in muscle function. Additionally, the company presented data supporting the development of novel promoters and capsids as part of its next generation gene therapy discovery efforts. These data were presented this week at the 21st Annual Meeting of The American Society of Gene and Cell Therapy in Chicago

https://bit.ly/2IthXpH